

Global Alprolix Market Set For 9.7% Growth, Reaching \$1.911 Billion By 2029

The Business Research Company's Alprolix Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, TURKS AND CAICOS ISLANDS, January 17, 2025 /EINPresswire.com/ -- Is the [Alprolix Market](#) Continuing To Grow?



The Alprolix market has witnessed significant growth in recent years. In 2024, the market size stood at \$1,199.50 million which is expected to grow to \$1,319.14 million in 2025, reflecting a compound annual growth rate CAGR of 10.0%. The growth during the historic period can be



Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!"

The Business Research Company

attributed to increasing prevalence of hemophilia B, rising awareness and early diagnosis of bleeding disorders, the growing adoption of personalized treatments, as well as favorable healthcare policies supporting rare disease treatment.

Get Your Free Sample of The Alprolix Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=19873&type=smp>

What Is Expected of the [Alprolix Market Size](#) in the Forecast Period?

The alprolix market size is anticipated to see rapid growth in the forthcoming years. It is expected to grow to \$1,911.25 million in 2029 at a compound annual growth rate CAGR of 9.7%. The growth during the forecast period can be attributed to personalized medicine, increasing adoption of extended half-life factor therapies, greater focus on improving treatment adherence and quality of life, as well as the expansion of healthcare infrastructure in emerging markets. A rise in awareness about bleeding disorders might also contribute to the growth.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/alprolix-global-market-report>

What Is Primarily Driving The Alprolix Market Growth?

The increasing prevalence of hemophilia B, a rare, inherited bleeding disorder caused by a deficiency or absence of clotting factor IX, also known as Christmas disease, is expected to spur the market growth going forward. Improved diagnostic techniques, better awareness, advancements in healthcare systems, and enhanced treatment options resulting in longer life expectancy of individuals with hemophilia have all contributed to the increased prevalence of the condition. Alprolix, a long-acting recombinant clotting factor IX, has proven beneficial for hemophilia B patients as it reduces the frequency of bleeding episodes and the need for infusions by providing extended protection through its prolonged half-life, thereby improving patients' quality of life.

Who Are The Key Players In The Alprolix Market?

Major companies operating in the alprolix market include Sanofi. These firms have played a significant role in shaping the market and driving its growth.

What Does the Alprolix Market Have In Store For The Future?

Recent years have seen significant advancements within the alprolix market, with a growing focus on innovative therapies to address unmet medical needs in hemophilia B treatment. In April 2024, Pfizer Inc., a US-based pharmaceutical manufacturing company, received U.S. FDA approval for Beqveztm, a gene therapy designed to treat hemophilia B. This marked a significant milestone in hemophilia treatment, potentially reducing or eliminating the need for routine clotting factor infusions.

How Is The Global Alprolix Market Segmented?

The Alprolix market report covers the following segments:

- 1 By Product: Recombinant Coagulation Factor IX; Plasma-Derived Coagulation Factor IX
- 2 By Formulation: Injectable Solution; Powder For Reconstitution
- 3 By Application: Hemophilia B Treatment; Prophylaxis; Surgery
- 4 By Distribution: Hospitals; Specialty Clinics; Online Pharmacies

Regional Insights: Which Regions are Leading in the Alprolix Market?

North America was the largest region in the Alprolix market in 2024. Other regions covered in the market report include Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa.

Browse similar reports by [The Business Research Company](#).

<https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report>

Acquired Hemophilia Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/acquired-hemophilia-treatment-global-market-report>

Bleeding Disorders Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report>

Learn more about us more:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has earned a reputation for offering comprehensive, data-rich research and unique industry insights. Powered by 1,500,000 datasets, in-depth secondary research and insights from industry leaders, we give you the information you need to stay ahead in the game.

Contact us at:

The Business Research Company:

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube:

https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/777862104>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.